Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $33.35 USD
Change Today +1.39 / 4.35%
Volume 2.5M
ACAD On Other Exchanges
As of 8:10 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

acadia pharmaceuticals inc (ACAD) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/10/15 - $46.48
52 Week Low
04/15/14 - $15.64
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

acadia pharmaceuticals inc (ACAD) Related Businessweek News

No Related Businessweek News Found

acadia pharmaceuticals inc (ACAD) Details

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. Its lead product candidate is NUPLAZID, which completed the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis; is in Phase II study for Alzheimer’s disease psychosis; and has completed Phase II trial for the treatment of schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

97 Employees
Last Reported Date: 02/26/15
Founded in 1993

acadia pharmaceuticals inc (ACAD) Top Compensated Officers

Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $605.0K
General Counsel, Corporate Compliance Officer...
Total Annual Compensation: $445.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $178.1K
Compensation as of Fiscal Year 2013.

acadia pharmaceuticals inc (ACAD) Key Developments

ACADIA Pharmaceuticals Inc. Appoints Daniel Soland to Board of Directors

ACADIA Pharmaceuticals Inc. announced that Daniel Soland has joined its Board of Directors. Mr. Soland is a seasoned pharmaceutical executive with over 30 years of experience in the biopharmaceutical industry. In addition to his extensive commercial experience in launching new drugs and life cycle management, he has led manufacturing and quality organizations and has been instrumental in driving growth in the companies he has served. Mr. Soland previously served as Senior Vice President and Chief Operating Officer of ViroPharma starting in 2008 until it was acquired in 2014, and as Vice President and Chief Commercial Officer of the Company from 2006 to 2008.

Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against ACADIA Pharmaceuticals Inc

Robbins Geller Rudman & Dowd LLP announced that a class action has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of ACADIA Pharmaceuticals Inc. publicly traded securities during the period between February 26, 2015 and March 11, 2015. The complaint charges ACADIA and certain of its officers and directors with violations of the Securities Exchange Act of 1934. The complaint alleges that during the Class Period, defendants made false and misleading statements and/or failed to disclose adverse facts regarding the timing of ACADIA’s submission of its New Drug Application ('NDA') to the FDA for NUPLAZID. As a result of defendants’ false and misleading statements or omissions during the Class Period, ACADIA securities traded at artificially inflated prices, with its stock trading at prices above $45 per share. On February 26, 2015, ACADIA announced its 2014 fourth quarter and year-end financial results (for the year ended December 31, 2014) and told investors it 'remained on track to submit New Drug Application to the FDA in the first quarter of 2015. Then, on March 11, 2015, ACADIA issued a press release announcing a change in the timing of its planned NDA submission to the FDA for NUPLAZID from the first quarter of 2015 to the second half of 2015. In a separate press release the same day, ACADIA announced the retirement of the Company’s Chief Executive Officer and director, Uli Hacksell. On this news, ACADIA common stock dropped $9.94 per share to close at $34.82 per share on March 12, 2015, a one-day decline of 22% on volume of 15 million shares. Plaintiff seeks to recover damages on behalf of all purchasers of ACADIA publicly traded securities during the Class Period. The plaintiff is represented by Robbins Geller, which has expertise in prosecuting investor class actions and extensive experience in actions involving financial fraud.

ACADIA Pharmaceuticals Inc. - Special Call

To discuss its planned NDA submission and the management change


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACAD:US $33.35 USD +1.39

ACAD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Acorda Therapeutics Inc $33.91 USD -0.29
Depomed Inc $22.83 USD +0.16
Impax Laboratories Inc $46.91 USD +1.17
Isis Pharmaceuticals Inc $64.81 USD +1.44
View Industry Companies

Industry Analysis


Industry Average

Valuation ACAD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26,593.4x
Price/Book 10.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23,991.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACADIA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at